Participants can now join a clinical trial to test antiviral COVID-19 treatments for use early on in the illness.
The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of covid-19 In the Community (PANORAMIC) is a national priority trial.
It aims to understand which treatments can help clinically vulnerable people recover sooner and prevent the need for hospital treatment.
PIF member Guy’s and St Thomas’ is a site for the trial, run by researchers from the University of Oxford and the National Institute for Health Research (NIHR).
The principle investigator at the trust is Dr Anna Goodman, consultant in infectious diseases.
COVID-19 antiviral treatments
PANORAMIC aims to rapidly evaluate several antiviral treatments that could help clinically vulnerable people with COVID-19 recover sooner.
This would prevent the need for hospital admission and ease the burden on the NHS.
The UK Antiviral Taskforce has selected all treatments to be tested.
The first to be investigated through the trial will be molnupiravir (brand name Lagevrio), a COVID-19 antiviral pill already licensed by the MHRA.
People can join the study if they are:
- Aged 50 and over
- Aged between 18 to 49 years with underlying health conditions that make them clinically more vulnerable
- Have been unwell with COVID-19 for less than five days.
All participants should have recorded a positive PCR test within the past seven days.
Participants will receive either the anti-viral treatment plus the current standard care, or the current standard of care without the new antiviral treatment.
Around 5,300 people will be recruited to each group – up to 10,600 volunteers in total will be needed.
To find out more, visit the PANORAMIC study website or call 08081 560 017.